Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of E110. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 3/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PTPRA | P18433 | 1/20 | 0.51 |
| ▸ | PTPRB | P23467 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E110 SCHEMBL323402 | 1.00 | THRB (1.00) | THRBCYP1A2CYP2C9PTPN1MAPT | |
| E110 SCHEMBL29350765 | 1.00 | THRB (1.00) | THRBCYP1A2CYP2C9PTPN1MAPT | |
| E110 SCHEMBL13276157 | 1.00 | THRB (1.00) | THRBCYP1A2CYP2C9PTPN1MAPT | |
| SCHEMBL12760915 | 0.97 | THRB (0.95) | THRBCYP1A2CYP2C9PTPN1MAPT | |
| SCHEMBL3196947 | 0.93 | THRB (0.88) | THRBCYP1A2CYP2C9PTPN1MAPT | |
| SCHEMBL29489969 | 0.93 | THRB (0.88) | THRBCYP1A2CYP2C9PTPN1MAPT | |
| SCHEMBL4808237 | 0.93 | THRB (0.88) | THRBCYP1A2CYP2C9PTPN1MAPT | |
| SCHEMBL30341067 | 0.92 | THRB (0.85) | THRBCYP1A2CYP2C9PTPN1MAPT | |
| SCHEMBL9343017 | 0.92 | THRB (0.85) | THRBCYP1A2CYP2C9PTPN1MAPT | |
| SCHEMBL29394731 | 0.92 | THRB (0.85) | THRBCYP1A2CYP2C9PTPN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116391906-A | Colorful cigar tobacco and preparation method thereof | 中国烟草总公司四川省公司 | 2023-07-07 | — | — | CN | claimed |
| EP-4114201-A1 | A STABLE FOOD-GRADE MICROCAPSULE FOR THE DELIVERY OF UNSTABLE AND FOOD-INCOMPATIBLE ACTIVE INGREDIENTS TO FOOD PRODUCTS | Nuversys Ltd. (IL) | 2023-01-11 | — | — | EP | claimed |
| US-20220235270-A1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2022-07-28 | — | — | US | claimed |
| EP-3986979-A1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | The University Court Of The University of Edinburgh (GB) | 2022-04-27 | — | — | EP | claimed |
| WO-2021176445-A1 | A STABLE FOOD-GRADE MICROCAPSULE FOR THE DELIVERY OF UNSTABLE AND FOOD-INCOMPATIBLE ACTIVE INGREDIENTS TO FOOD PRODUCTS | NUVERSYS LTD. (IL) | 2021-09-10 | — | — | WO | claimed |
| WO-2020254813-A1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-12-24 | — | — | WO | claimed |
| EP-2930126-B1 | Fashionable aerosol dye | HENKEL AG & CO KGAA (DE) | 2019-10-09 | — | — | EP | claimed |
| JP-56120665-A | — | — | None | — | — | JP | disclosed |
| US-12491157-B1 | Atomoxetine hydrochloride oral suspension and use thereof | OWP Pharmaceuticals, Inc. | 2025-12-09 | — | — | US | disclosed |
| US-12478584-B1 | Atomoxetine hydrochloride oral suspension and use thereof | OWP PHARMACEUTICALS INC (US) | 2025-11-25 | — | — | US | disclosed |
| US-12460135-B2 | System comprising a nematic liquid crystal and an interface | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-11-04 | — | — | US | disclosed |
| EP-4054523-B1 | ORALLY ADMINISTRABLE FILMS COMPRISING POORLY WATER SOLUBLE ACTIVE INGREDIENTS AND PREPARATION THEREOF | BIOTA LTD (IL) | 2025-08-06 | — | — | EP | disclosed |
| EP-3986979-B1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | UNIV COURT UNIV OF EDINBURGH (GB) | 2025-07-30 | — | — | EP | disclosed |
| EP-0229191-B1 | FLY-ATTRACTIVE COMPOSITION | EARTH CHEMICAL CO., LTD. (JP) | 1993-06-02 | — | — | EP | disclosed |
| US-4871723-A | 1A,24-DIHYDROXYCHOLECALCIFEROL; OILY CARRIER; FATTY ACID ESTER , FATTY ALCOHOL OR PROPYLENE CARBONATE AS SOLVENT | TEIJIN, LIMITED (JP) | 1989-10-03 | — | — | US | disclosed |
| US-4855133-A | Composition for attracting flies | EARTH CHEMICAL COMPANY, LIMITED (JP) | 1989-08-08 | — | — | US | disclosed |
| EP-0229191-A1 | FLY-ATTRACTIVE COMPOSITION | EARTH CHEMICAL CO., LTD. (JP) | 1987-07-22 | — | — | EP | disclosed |
| EP-0177920-A2 | Pharmaceutical composition for external use containing active type vitam D3 | TEIJIN LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| JP-S56120665-A | STABILIZING METHOD OF RETINOL FATTY ACID ESTER | KANEBO LTD | 1981-09-22 | — | — | JP | disclosed |
| US-3961085-A | Edible food casing dyed with an edible dyestuff and process for its manufacture | WINKLER BRUNO | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491157-B1 | Atomoxetine hydrochloride oral suspension and use thereof | SLC6A4, SLC6A3, MBOAT4 | THRB 1816/4885PTGS1 4292/4885PTGS2 4452/4885 |
| US-12478584-B1 | Atomoxetine hydrochloride oral suspension and use thereof | SLC6A4, SLC6A3, MBOAT4 | THRB 1816/4885PTGS1 4292/4885PTGS2 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.